LAS VEGAS, May 28, 2024 /PRNewswire/ -- JanOne Inc. (Nasdaq: JAN) a multidisciplinary organization with a focus on healthcare and fintech, announced today that its Fintech subsidiary, ALT 5 Sigma, will be presenting at the iFX Expo, the World's largest online trading conference and tradeshow held on June 18 until June 20 in Limassol, Cyprus. https://cyprus2024.ifxexpo.com/

The iFX Expo brings together thousands of C-Level Executives and Industry Peers from 120 countries. The Online Trading Platform Market was valued at $9.1 Billion in 2022 and is projected to grow to $16.5 Billion by 2032.¹ Online Trading Platforms represent a growing market segment for "ALT 5 Pay" though their ability to enable the acceptance of cryptocurrency payments and deposits.

"Our inroads into the Online Trading Platforms market has been one of our fastest growing market segments. Presenting at the iFX Expo will help us further our relationships with existing leading online platforms clients and ISOs and foster new ones," said Mr. Andre Beauchesne, President of Alt 5 Sigma Inc., adding "We look forward to seeing everyone at our booth."

According to ResearchandMarkets.com, "The Payment Processing Solutions Market size is estimated to grow from approximately USD 100 Billion in 2023 at a CAGR of 9.5% during the forecast period from 2023 to 2030." In addition, the report states, "Technological advancements, including artificial intelligence, machine learning, and blockchain, are revolutionizing the payment processing landscape."²

About ALT 5 Sigma Inc.

Launched in 2018, ALT 5 is a fintech company that provides next generation blockchain-powered technologies to enable a migration to a new global financial paradigm. ALT 5, through its subsidiaries, offers two main platforms to its customers: "ALT 5 Pay" and "ALT 5 Prime."

ALT 5 Pay is a crypto-currency payment gateway that enables registered and approved global merchants to accept and make crypto-currency payments or to integrate the ALT 5 Pay payment platform into their application or operations using the plugin with WooCommerce and or ALT 5 Pay's checkout widgets and APIs. Merchants have the option to convert to fiat currency (US Dollars, Canadian Dollars, Euros, and British Pounds Sterling) automatically or to receive their payment in digital assets.

ALT 5 Prime is an electronic over-the-counter trading platform that enables registered and approved customers to buy and sell digital assets. Customers can purchase digital assets with fiat and, equally, can sell digital assets and receive fiat. ALT 5 Prime is available through a browser-based access mobile phone application named "ALT 5 Pro" that can be downloaded from the Apple App Store, from Google Play, through ALT 5 Prime's FIX API, as well as through Broadridge Financial Solutions' NYFIX gateway for approved customers.

About JanOne

JanOne is a unique Nasdaq-listed multidisciplinary organization with a focus on healthcare and fintech.  Through its fintech focus (ALT 5), JanOne provides next generation blockchain-powered technologies to enable a migration to a new global financial paradigm and offers two main platforms to its customers: "ALT 5 Pay" and "ALT 5 Prime."  Through its healthcare focus, JanOne offers innovative, actionable solutions intended to help end the opioid crisis. JanOne is dedicated to funding resources toward innovation, technology, and education to find a key resolution to the national opioid epidemic, which is one of the deadliest and most widespread in the nation's history. Its drugs in the clinical trial pipeline have shown promise for their innovative targeting of the causes of pain as a strategic option for physicians averse to exposing patients to addictive opioids.

Please visit www.janone.com for additional information.

Forward Looking Statements

This press release contains statements that are forward-looking statements as defined within the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements and links relating to the profitability and prospective growth of ALT 5's platforms and business, including, but not limited to international currency risks, third-party or customer credit risks, liability claims stemming from Alt 5's services, and technology challenges for future growth or expansion.  This press release also contains statements relating to the statements that JAN 101 will treat PAD, that JAN 123 will treat CRPS, the timing of the commencement of clinical trials, that the FDA will permit approval through a 505(b)(2) pathway for JAN 123, that upon approval JAN 101 will immediately disrupt the PAD market, and other statements, including words such as "continue", "expect", "intend", "will", "hope" "should", "would", "may", "potential" and other similar expressions. Such statements reflect JanOne's current view with respect to future events, are subject to risks and uncertainties, and are necessarily based upon a number of estimates and assumptions that, while considered reasonable by JanOne, are inherently subject to significant business, economic, competitive, political and social uncertainties and contingencies.

Many factors could cause JanOne's actual results, performance or achievements to be materially different from any future results, performance or achievements described in this press release. Such factors could include, among others, those detailed in the Company's periodic reports filed with the Securities and Exchange Commission (the "SEC"). Should one or more of these risks or uncertainties materialize, or should the assumptions set out in the section entitled "Risk Factors" in JanOne's filings with the SEC underlying those forward-looking statements prove incorrect, actual results may vary materially from those described herein. These forward-looking statements are made as of the date of this press release and JanOne does not intend, and does not assume any obligation, to update these forward-looking statements, except as required by law. JanOne cannot assure that such statements will prove to be accurate as actual results and future events could differ materially from those anticipated in such statements. Individuals are cautioned that forward-looking statements are not guarantees of future performance and accordingly investors are cautioned not to put undue reliance on forward-looking statements due to the inherent uncertainty therein.

Media Contact Investor Relations
This email address is being protected from spambots. You need JavaScript enabled to view it.
1-800-400-2247